

# Step-by-step Time-Complexity Derivation for DEvIRank Path Aggregation ( $L_{\max}=3$ , Shortest Paths)

This note provides a step-by-step derivation of the per-drug time complexity for the DEvIRank scoring term that aggregates contributions over shortest paths of bounded length (maximum length  $L = 3$ ) in a weighted protein–protein interaction (PPI) network.

## 1 Notation and Assumptions

Let  $G = (V, E)$  be the PPI graph with  $|V|$  nodes and  $|E|$  edges.

Let  $S$  be the set of drug target proteins and  $T$  the set of disease-associated proteins.

Let  $\Delta$  denote the maximum node degree in  $G$ , and  $\deg(v)$  the degree of node  $v$ .

We enumerate only sample paths (no repeated nodes) with length at most  $L = 3$ .

We assume  $O(1)$  lookup for membership in  $T$ .

We analyze the dominant path-aggregation term used to score a drug  $d$ :

$$w_d(d) = \sum_{s \in S} DGI_t * \left( \sum_{\substack{t \in T, \\ p \in P[s \rightarrow t]}} \left( \prod_{e \in p} PPI_e * \left( 1 + \sum_{n \in N[t]} PPI_n \right) \right) \right)$$

where  $N[t]$  denotes the set of edges connecting protein  $t$  to its neighboring proteins,  $P[s \rightarrow t]$  denotes the set of paths from  $s$  to  $t$ ,  $e$  represents an edge along path  $p$ , and  $PPI_e$  is the confidence score of interaction  $e$ .

The per-path work includes multiplying up to 3 edge weights ( $PPI_e$ ) and a constant number of scalar multiplications/additions. Thus, the cost per enumerated path is  $O(1)$  when  $L$  is a small constant.

## 2 Step A: Compute Disease Weights $w_t(t)$

The disease weight for each  $t \in T$  is:

$$w_t(t) = \sum_{n \in N[t]} PPI_n$$

Computing  $w_t(t)$  for a single  $t$  visits all incident edges once, costing  $O(\deg(t))$ . Therefore, computing all disease weights costs:

$$T_{\text{total-disease-targets}} = O(\sum_{t \in T} \deg(t))$$

### 3 Step B: Bound the Number of Shortest Paths from a Fixed s (L<sub>max</sub>=3)

We bound the number of candidate simple paths starting at a fixed drug target node  $s$ , for lengths 0, 1, 2, and 3.

**Length 0 (zero edge):** disease target node  $t$  is the drug target  $s$ .

$$\#paths_{len0}(s) = 1$$

**Length 1 (one edge):** the number of neighbors is at most  $\deg(s)$ .

$$\#paths_{len1}(s) \leq \deg(s)$$

**Length 2 (two edges):** after choosing the first neighbor, the second step can go to at most  $(\Delta - 1)$  new nodes (we cannot return to  $s$  if paths are simple).

$$\#paths_{len2}(s) \leq \deg(s) \cdot (\Delta - 1)$$

**Length 3 (three edges):** similarly, after two steps, the third step has at most  $(\Delta - 1)$  choices again to avoid revisiting the previous node(s), yielding:

$$\#paths_{len3}(s) \leq \deg(s) \cdot (\Delta - 1)^2$$

Thus, the total number of simple paths from  $s$  of length at most 3 is bounded by:

$$\begin{aligned} \#paths_{len \leq 3}(s) &\leq 1 + \deg(s) + \deg(s)(\Delta - 1) + \deg(s)(\Delta - 1)^2 \\ &\Rightarrow T_{paths}(s) = O(\deg(s) \Delta^2) \end{aligned}$$

Where  $\Delta$  denotes the maximum degree of the PPI network.

### 4 Step C: Total Path Enumeration Cost Over All Drug Targets

Because the work per enumerated path is  $O(1)$  for  $L_{max} = 3$ , the time to enumerate and score all bounded-length paths originating from  $s$  is:

$$T_{paths}(s) = O(\deg(s) \Delta^2)$$

Summing over all  $s \in S$  gives the per-drug path aggregation cost:

$$T_{total\ path\ from\ s\ to\ T} = O\left(\sum_{s \in S} \deg(s) \Delta^2\right)$$

A simple worst-case bound follows from  $\deg(s) \leq \Delta$  for all  $s$ :

$$T_{total\ path\ from\ s\ to\ T} = O(|S| \Delta^3) \text{ (worst case)}$$

### 5 Final Per-Drug Time Complexity

Computations from steps 2,3 and 4 yields:

$$T_{total} = O\left(\sum_{t \in T} \deg(t) + \sum_{s \in S} \deg(s) \Delta^2\right)$$

and in the worst case:

$$T_{total} = O\left(\sum_{t \in T} \deg(t) + |S| \Delta^3\right)$$

## 6 Notes on Practical Implementation

- 1) The bound assumes path enumeration is performed from each  $s$  and endpoints are checked against  $T$  in  $O(1)$ .
- 2) Restricting to shortest paths avoids repeated-node walks, which would otherwise increase path counts.
- 3) Since drugs are independent, total runtime scales linearly with the number of drugs and is embarrassingly parallel across drugs.